For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
"Probably any words I use to describe my emotions at seeing this data will understate it," said Daniel Skovronsky, Eli Lilly's head scientist.
News
STAT+: Third Rock Ventures plots next chapter after raising $1.1 billion fund
Third Rock Venture partners Abbie Celniker and Reid Huber spoke with STAT about their plans for investing their sixth and largest fund. The lion’s share of the $1.1 billion they… […]
News
STAT+: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
Element’s machine can now read a whole human genome for as little as $200 — the cost of a couple trips to the grocery store. […]
News
STAT+: In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients
The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared to chemotherapy in patients with the most common form of metastatic breast cancer. […]
